Addex Therapeutics Ltd (ADXN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed May 15, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ADXN SEC filings page.
Addex Therapeutics Ltd (ADXN) reported $5.0M in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
Sparse FY2025 reporting leaves Addex's operating model and financing structure largely unobservable
The available FY2025 figures pair$5M of revenue with no populated profitability or cash-flow measures, so the reported data cannot distinguish commercial activity from investment-stage operations.
Revenue is reported, but the absence of assets, liabilities, and cash-flow data prevents an assessment of capital intensity, liquidity, or solvency.
The reported share count of 147.8M provides scale context, yet without earnings or equity values it cannot be connected to per-share economics or financing dependence.
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
We are recalculating Addex Therapeutics Ltd's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Addex Therapeutics Ltd generated $5.0M in revenue in fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
None of these metrics is reported for fiscal year 2025.
ADXN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F |
|---|---|
| Revenue | $5.0M |
| Diluted Shares (Avg) | 107M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted).
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Addex Therapeutics Ltd ADXN | FY2025 | $5.0M | N/A | N/A | $4.1M | — |
| ESSA Pharma Inc. EPIX | FY2024 | N/A | -$28.5M | N/A | $9.5M | — |
| Processa Pharmaceuticals, Inc. PCSA | FY2025 | N/A | $13.6M | N/A | $5.3M | — |
| VivoSim Labs, Inc. VIVS | FY2026 | $131K | -$13.8M | N/A | $3.8M | — |
| Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock CYCCP | FY2025 | $747K | $3.0M | N/A | $9.6M | — |
Where Addex Therapeutics Ltd Ranks
Frequently Asked Questions
What is Addex Therapeutics Ltd's annual revenue?
Addex Therapeutics Ltd (ADXN) reported $5.0M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
What is Addex Therapeutics Ltd's P/E ratio?
Addex Therapeutics Ltd (ADXN) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $4.1M as of Sep 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Addex Therapeutics Ltd's price-to-sales ratio?
Addex Therapeutics Ltd (ADXN) trades at 0.8x sales, its market capitalization divided by revenue of $5.0M revenue, FY2025. The market capitalization is $4.1M as of Sep 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.